418 related articles for article (PubMed ID: 23405972)
41. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
43. [The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation].
Xu LP; Liu DH; Liu KY; Zhang CL; Wang FR; Wang JZ; Wang Y; Chen H; Zhang YY; Yan CH; Han W; Chen YH; Zhao T; Zhang XH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):966-70. PubMed ID: 23327959
[TBL] [Abstract][Full Text] [Related]
44. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.
Bordon V; Padalko E; Benoit Y; Dhooge C; Laureys G
Pediatr Transplant; 2012 Mar; 16(2):144-50. PubMed ID: 22288846
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
46. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
47. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study.
Dumas PY; Ruggeri A; Robin M; Crotta A; Abraham J; Forcade E; Bay JO; Michallet M; Bertrand Y; Socié G; Ionescu I; Gluckman E; Milpied N; Rocha V
Bone Marrow Transplant; 2013 Feb; 48(2):253-6. PubMed ID: 22773124
[TBL] [Abstract][Full Text] [Related]
48. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients.
Aalto SM; Juvonen E; Tarkkanen J; Volin L; Haario H; Ruutu T; Hedman K
Clin Infect Dis; 2007 Nov; 45(10):1305-9. PubMed ID: 17968825
[TBL] [Abstract][Full Text] [Related]
49. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
50. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
[TBL] [Abstract][Full Text] [Related]
51. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
52. Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation.
Loginov R; Aalto S; Piiparinen H; Halme L; Arola J; Hedman K; Höckerstedt K; Lautenschlager I
J Clin Virol; 2006 Oct; 37(2):104-8. PubMed ID: 16931140
[TBL] [Abstract][Full Text] [Related]
53. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.
Jain T; Kosiorek HE; Grys TE; Kung ST; Shah VS; Betcher JA; Slack JL; Leis JF; Khera N; Noel P; Palmer JM; Sproat LZ
Leuk Lymphoma; 2019 Jan; 60(1):110-117. PubMed ID: 29979906
[TBL] [Abstract][Full Text] [Related]
54. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
[TBL] [Abstract][Full Text] [Related]
55. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
Papalexandri A; Gavriilaki E; Vardi A; Kotsiou N; Demosthenous C; Constantinou N; Touloumenidou T; Zerva P; Kika F; Iskas M; Batsis I; Mallouri D; Yannaki E; Anagnostopoulos A; Sakellari I
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003218
[TBL] [Abstract][Full Text] [Related]
56. [Epstein-Barr virus (EBV) infections in patients treated with allogenic hematopoietic cells transplantation (allo-HCT)].
Zawilińska B; Piatkowska-Jakubas B; Kopeć J; Daszkiewicz E; Kleszcz E; Szostek S; Mensah-Glanowska P; Hawrylecka D; Skotnicki A
Przegl Epidemiol; 2006; 60(1):87-92. PubMed ID: 16758744
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
58. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
[TBL] [Abstract][Full Text] [Related]
59. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
[TBL] [Abstract][Full Text] [Related]
60. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
